Greenwich Wealth Management LLC trimmed its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 2.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 10,973 shares of the exchange traded fund’s stock after selling 284 shares during the period. Greenwich Wealth Management LLC’s holdings in SPDR S&P Biotech ETF were worth $988,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the business. Addison Advisors LLC increased its holdings in SPDR S&P Biotech ETF by 27.4% in the 4th quarter. Addison Advisors LLC now owns 535 shares of the exchange traded fund’s stock worth $48,000 after buying an additional 115 shares in the last quarter. Signature Estate & Investment Advisors LLC increased its holdings in SPDR S&P Biotech ETF by 5.7% in the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock worth $231,000 after buying an additional 125 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in SPDR S&P Biotech ETF by 0.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,873 shares of the exchange traded fund’s stock worth $2,373,000 after buying an additional 148 shares in the last quarter. Invst LLC boosted its position in SPDR S&P Biotech ETF by 6.0% in the third quarter. Invst LLC now owns 2,807 shares of the exchange traded fund’s stock worth $277,000 after purchasing an additional 160 shares during the last quarter. Finally, Beech Hill Advisors Inc. boosted its position in SPDR S&P Biotech ETF by 2.5% in the fourth quarter. Beech Hill Advisors Inc. now owns 6,655 shares of the exchange traded fund’s stock worth $599,000 after purchasing an additional 162 shares during the last quarter.
SPDR S&P Biotech ETF Stock Performance
Shares of NYSEARCA:XBI opened at $87.13 on Friday. The stock has a market capitalization of $5.65 billion, a price-to-earnings ratio of 11.47 and a beta of 0.99. The stock’s 50-day simple moving average is $90.06 and its two-hundred day simple moving average is $94.82. SPDR S&P Biotech ETF has a 52-week low of $81.14 and a 52-week high of $105.47.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- What is Short Interest? How to Use It
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is MarketRank™? How to Use it
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is a Bond Market Holiday? How to Invest and Trade
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.